PROGRESSING DIRECTED THERAPIES USING MOLECULAR IMAGING

  • Pramod Khatri 1Genetics Division, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi 110029, India

Abstract

The clinical studies that are using fluorine-18 tracers succumb to four general sorts: treatment planning, either for
pharmaceutical therapy or radiation therapy; prescient or reaction marker studies for new pharmaceutical utilizing
established tracer; development of new tracer for clinical-sickness diagnosis; and improvement of new biomarker for pharmaceutical therapy. The foremost two include tracers with past clinical experience while the recent incorporate various Phase 1 studies to confirm the safety, dosimetry, and best imaging parameters of a new tracer. The clinical provision may be to utilize the new tracer as an affirmed demonstrative apparatus for ailment diagnosis or for use as a clinical research and development tool. The last classification represents for the most active zone, an impression of the solid interest in the utilization of fluorine-18 PET imaging in drug development and discovery.
KEYWORDS: PET imaging, Electrophilic, Fluorine-18-fluorodeoxyglucose, FDA

Published
2013-08-30
How to Cite
Khatri, P. (2013). PROGRESSING DIRECTED THERAPIES USING MOLECULAR IMAGING. Journal of Biomedical and Pharmaceutical Research, 2(4). Retrieved from https://jbpr.in/index.php/jbpr/article/view/475
Section
Review Articles